copanlisib   Click here for help

GtoPdb Ligand ID: 7875

Synonyms: Aliqopa® | BAY 80-6946 | BAY80-6946
Approved drug PDB Ligand
copanlisib is an approved drug (FDA (2017))
Compound class: Synthetic organic
Comment: Copanlisib is a phosphoinositide 3-kinase (PI3K) inhibitor [2], preferentially inhibiting PI3Kα and PI3Kβ, and with significant antineoplastic activity [3]. The compound has less potent mTOR activity.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 142.01
Molecular weight 480.22
XLogP 1.76
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES COc1c(OCCCN2CCOCC2)ccc2c1nc(=NC(=O)c1cnc(nc1)N)n1c2NCC1
Isomeric SMILES COc1c(OCCCN2CCOCC2)ccc2c1nc(=NC(=O)c1cnc(nc1)N)n1c2NCC1
InChI InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14,25H,2,5-12H2,1H3,(H2,24,26,27)
No information available.
Summary of Clinical Use Click here for help
In September 2017, copanlisib received FDA approval for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic treatments. The EMA granted orphan drug designation for copanlisib in August 2018, as a treatment for marginal zone lymphoma [1].
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible cell populations.